The post Harvard Boosts Bitcoin Exposure During Market Turmoil appeared on BitcoinEthereumNews.com. Bitcoin Bitcoin ETFs may be experiencing one of their worst weeks since launch, yet in the middle of the sell-off, a surprising buyer has quietly emerged. Key Takeaways: Harvard boosted its Bitcoin ETF holdings sharply during the market decline. ETF outflows continue even as long-term investors accumulate. Market split widens between panic sellers and strategic buyers.  Harvard University, better known for its centuries-old endowment traditions and cautious investment playbook, has sharply increased its exposure to Bitcoin. Instead of reducing risk during the market decline, the institution has dramatically expanded it. Multibillion-Dollar Endowment Turns Toward Digital Assets The latest filing shows that Harvard now holds 6.81 million shares of BlackRock’s IBIT, a position valued at nearly $442.8 million at the end of September. Only three months earlier, the endowment had reported 1.9 million shares. The change is so large that it instantly pushes the university into the top tier of institutional holders of the world’s largest Bitcoin ETF. It represents not a tactical trade but a strategic reallocation, especially when placed alongside the other major shift in the filing: a near doubling of its gold ETF position, now worth approximately $235 million. Harvard Accumulates While Others Exit What makes Harvard’s acquisition even more striking is the contrast with the broader market mood. Throughout the past few days, nearly every Bitcoin ETF has been crushed by aggressive redemptions. The most dramatic wave came on Thursday, when almost $870 million exited the products in a single trading session, followed by another $492 million the next day. This retreat has translated directly into price pressure. Bitcoin slipped again in the past 24 hours, settling near $96,261 after briefly dipping closer to $95,000. A Contrarian Bet on the Long-Term While smaller investors appear to be reducing exposure and institutions with short-term liquidity needs continue to… The post Harvard Boosts Bitcoin Exposure During Market Turmoil appeared on BitcoinEthereumNews.com. Bitcoin Bitcoin ETFs may be experiencing one of their worst weeks since launch, yet in the middle of the sell-off, a surprising buyer has quietly emerged. Key Takeaways: Harvard boosted its Bitcoin ETF holdings sharply during the market decline. ETF outflows continue even as long-term investors accumulate. Market split widens between panic sellers and strategic buyers.  Harvard University, better known for its centuries-old endowment traditions and cautious investment playbook, has sharply increased its exposure to Bitcoin. Instead of reducing risk during the market decline, the institution has dramatically expanded it. Multibillion-Dollar Endowment Turns Toward Digital Assets The latest filing shows that Harvard now holds 6.81 million shares of BlackRock’s IBIT, a position valued at nearly $442.8 million at the end of September. Only three months earlier, the endowment had reported 1.9 million shares. The change is so large that it instantly pushes the university into the top tier of institutional holders of the world’s largest Bitcoin ETF. It represents not a tactical trade but a strategic reallocation, especially when placed alongside the other major shift in the filing: a near doubling of its gold ETF position, now worth approximately $235 million. Harvard Accumulates While Others Exit What makes Harvard’s acquisition even more striking is the contrast with the broader market mood. Throughout the past few days, nearly every Bitcoin ETF has been crushed by aggressive redemptions. The most dramatic wave came on Thursday, when almost $870 million exited the products in a single trading session, followed by another $492 million the next day. This retreat has translated directly into price pressure. Bitcoin slipped again in the past 24 hours, settling near $96,261 after briefly dipping closer to $95,000. A Contrarian Bet on the Long-Term While smaller investors appear to be reducing exposure and institutions with short-term liquidity needs continue to…

Harvard Boosts Bitcoin Exposure During Market Turmoil

Bitcoin

Bitcoin ETFs may be experiencing one of their worst weeks since launch, yet in the middle of the sell-off, a surprising buyer has quietly emerged.

Key Takeaways:
  • Harvard boosted its Bitcoin ETF holdings sharply during the market decline.
  • ETF outflows continue even as long-term investors accumulate.
  • Market split widens between panic sellers and strategic buyers. 

Harvard University, better known for its centuries-old endowment traditions and cautious investment playbook, has sharply increased its exposure to Bitcoin. Instead of reducing risk during the market decline, the institution has dramatically expanded it.

Multibillion-Dollar Endowment Turns Toward Digital Assets

The latest filing shows that Harvard now holds 6.81 million shares of BlackRock’s IBIT, a position valued at nearly $442.8 million at the end of September. Only three months earlier, the endowment had reported 1.9 million shares.

The change is so large that it instantly pushes the university into the top tier of institutional holders of the world’s largest Bitcoin ETF. It represents not a tactical trade but a strategic reallocation, especially when placed alongside the other major shift in the filing: a near doubling of its gold ETF position, now worth approximately $235 million.

Harvard Accumulates While Others Exit

What makes Harvard’s acquisition even more striking is the contrast with the broader market mood. Throughout the past few days, nearly every Bitcoin ETF has been crushed by aggressive redemptions.

The most dramatic wave came on Thursday, when almost $870 million exited the products in a single trading session, followed by another $492 million the next day. This retreat has translated directly into price pressure. Bitcoin slipped again in the past 24 hours, settling near $96,261 after briefly dipping closer to $95,000.

A Contrarian Bet on the Long-Term

While smaller investors appear to be reducing exposure and institutions with short-term liquidity needs continue to raise cash by selling ETF shares, Harvard is behaving as if the current downturn represents an entry zone rather than an exit trigger.

It is an approach that resonates more with long investment horizons than with weekly volatility, and it stands in sharp contrast to the pessimism that dominated conversations around Bitcoin in elite academic circles just a few years ago. A Harvard economist once publicly argued that Bitcoin was more likely to fall to $100 than rise beyond $100,000 before 2028. Bitcoin has already crossed the $120,000 mark well ahead of that timeline.

Institutional Divergence Widens

Harvard is not the only entity taking the contrarian path. A separate filing shows that Al Warda Investments enlarged its exposure to IBIT as well, now controlling 7.96 million shares valued at roughly $517.6 million. Yet outside of those rare cases, the ETF landscape remains dominated by withdrawals rather than accumulation.

The result is an unusual market split. Panic and profit-taking dominate one side of the Bitcoin ecosystem, while deep-pocket investors with patient timeframes are expanding their bets. Whether Harvard’s move will be remembered as strategic foresight or misplaced confidence will depend on how Bitcoin behaves long after today’s selling cycle has faded.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Author

Alex is an experienced financial journalist and cryptocurrency enthusiast. With over 8 years of experience covering the crypto, blockchain, and fintech industries, he is well-versed in the complex and ever-evolving world of digital assets. His insightful and thought-provoking articles provide readers with a clear picture of the latest developments and trends in the market. His approach allows him to break down complex ideas into accessible and in-depth content. Follow his publications to stay up to date with the most important trends and topics.

Next article

Source: https://coindoo.com/harvard-boosts-bitcoin-exposure-during-market-turmoil/

Market Opportunity
Belong Logo
Belong Price(LONG)
$0.003627
$0.003627$0.003627
-0.63%
USD
Belong (LONG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26